Management of Antineoplastic Extravasation: ONS-ASCO Guideline

About this episode

Dr. Tanya Thomas and Dr. Aparna Jotwani discuss the new guidelines for managing antineoplastic extravasation.

Dr. Tanya Thomas and Dr. Aparna Jotwani join the podcast to discuss the new Oncology Nursing Society and American Society of Clinical Oncology evidence-based guideline on the management of antineoplastic extravasation. They discuss recommendations from the expert panel on: management of extravasation of vesicant or irritant with vesicant properties antineoplastic agents, management of extravasation of paclitaxel or docetaxel, use & duration of thermal compress, and escalation of care. They share the importance of this comprehensive interdisciplinary guideline, highlight the algorithm as a useful tool for clinicians, and outline the outstanding questions related to the management of extravasation. Read the full guideline, "ONS/ASCO Guideline on the Management of Antineoplastic Extravasation" at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/supportive-care-guidelines . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice , https://ascopubs.org/doi/10.1200/OP-25-00579 Brittany Harvey: Hello and welcome to the ASCO Guidelines…

People in this episode

Host: Brittany Harvey

Guests: Dr. Tanya Thomas, Dr. Aparna Jotwani

Topics covered

• antineoplastic extravasation
• oncology nursing
• clinical guidelines
• patient care
• interdisciplinary approach

Keywords

• extravasation
• vesicant agents
• paclitaxel
• docetaxel
• thermal compress
• escalation of care
• clinical guidelines

Mentioned in this episode

Organizations: Oncology Nursing Society, American Society of Clinical Oncology, ASCO

Books & works: ONS/ASCO Guideline on the Management of Antineoplastic Extravasation

More episodes of ASCO Guidelines

• Systemic Treatment of Thyroid Cancer Guideline · April 1, 2026 · 23 min
• Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update · February 26, 2026 · 29 min
• White Blood Cell Growth Factors Guideline Update · February 25, 2026 · 23 min
• Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2 · February 3, 2026 · 20 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min